| Literature DB >> 30217229 |
Mehri Jamilian1, Shirin Mansury1, Fereshteh Bahmani2, Zahra Heidar3, Elaheh Amirani2, Zatollah Asemi4.
Abstract
BACKGROUND: The aim of this study was to evaluate the effect of the co-administration of probiotic and selenium on parameters of mental health, hormonal profiles, and biomarkers of inflammation and oxidative stress in women with PCOS. Data on the effects of selenium and probiotic co-supplementation on mental health, hormonal and inflammatory parameters of patients with polycystic ovary syndrome (PCOS) are scarce. This investigation was carried out to evaluate the effects of selenium and probiotic co-supplementation on mental health, hormonal and inflammatory parameters in women with PCOS.Entities:
Keywords: Hormonal profiles; Inflammatory markers; Mental health; Polycystic ovary syndrome; Probiotic; Selenium
Mesh:
Substances:
Year: 2018 PMID: 30217229 PMCID: PMC6137747 DOI: 10.1186/s13048-018-0457-1
Source DB: PubMed Journal: J Ovarian Res ISSN: 1757-2215 Impact factor: 4.234
Fig. 1Summary of patient flow diagram
General characteristics of study participants
| Placebo group ( | Probiotic plus selenium group ( | Pa | |
|---|---|---|---|
| Age (y) | 25.6 ± 3.8 | 26.0 ± 5.3 | 0.71 |
| Height (cm) | 161.6 ± 4.7 | 161.0 ± 4.4 | 0.63 |
| Weight at study baseline (kg) | 63.4 ± 7.7 | 63.9 ± 9.3 | 0.79 |
| Weight at end-of-trial (kg) | 63.2 ± 7.6 | 63.5 ± 9.2 | 0.86 |
| Weight change (kg) | −0.2 ± 0.7 | −0.4 ± 0.5 | 0.23 |
| BMI at study baseline (kg/m2) | 24.0 ± 3.0 | 24.6 ± 3.3 | 0.67 |
| BMI at end-of-trial (kg/m2) | 24.2 ± 3.0 | 24.5 ± 3.3 | 0.73 |
| BMI change (kg/m2) | −0.1 ± 0.3 | −0.2 ± 0.2 | 0.23 |
Data are means± SDs
aObtained from independent-samples t-test
Mental health and metabolic profiles at baseline and after the 12-week intervention in women with polycystic ovary syndrome that received either probiotic plus selenium supplements or placeboa
| Variables | Placebo group ( | Probiotic plus selenium group ( | Difference in outcome measures between probiotic plus selenium and placebo groupsa | |||
|---|---|---|---|---|---|---|
| Baseline | Week 12 | Baseline | Week 12 | β (95% CI) | Pb | |
| BDI total scores | 15.6 ± 4.4 | 15.3 ± 4.7 | 15.5 ± 4.0 | 14.4 ± 3.7 | −0.76 (−1.26, − 0.26) | 0.003 |
| GHQ scores | 45.4 ± 8.1 | 44.6 ± 8.2 | 44.2 ± 7.3 | 42.4 ± 6.7 | −1.15 (− 1.97, −0.32) | 0.007 |
| DASS scores | 86.3 ± 13.1 | 85.1 ± 12.9 | 85.1 ± 11.2 | 82.5 ± 10.9 | −1.49 (−2.59, −0.39) | 0.009 |
| Total testosterone (ng/mL) | 1.3 ± 0.5 | 1.3 ± 0.4 | 1.4 ± 0.7 | 1.1 ± 0.6 | −0.26 (− 0.51, − 0.02) | 0.03 |
| SHBG (nmol/L) | 40.3 ± 17.5 | 40.4 ± 18.3 | 47.1 ± 19.7 | 49.5 ± 22.1 | 1.82 (−1.77, 5.42) | 0.31 |
| mF-G scores | 13.0 ± 3.7 | 13.0 ± 3.6 | 14.5 ± 3.2 | 14.0 ± 2.9 | −0.43 (−0.74, − 0.11) | 0.008 |
| hs-CRP (mg/L) | 2.5 ± 1.6 | 2.7 ± 1.5 | 2.4 ± 1.5 | 2.0 ± 1.5 | −0.58 (− 0.97, − 0.19) | 0.004 |
| NO (μmol/L) | 36.5 ± 3.8 | 36.8 ± 4.0 | 36.6 ± 2.3 | 37.8 ± 3.5 | 0.94 (−0.65, 2.54) | 0.24 |
| TAC (mmol/L) | 909.9 ± 110.8 | 909.4 ± 122.7 | 933.3 ± 59.8 | 1012.9 ± 69.4 | 84.76 (48.08, 121.44) | < 0.001 |
| GSH (μmol/L) | 496.4 ± 88.1 | 497.8 ± 88.3 | 528.3 ± 88.3 | 552.9 ± 83.1 | 26.78 (4.33, 49.23) | 0.02 |
| MDA (μmol/L) | 2.4 ± 0.5 | 2.6 ± 0.7 | 2.8 ± 0.2 | 2.5 ± 0.2 | −0.29 (−0.56, −0.02) | 0.03 |
Data are mean ± SDs
a“Outcome measures” refers to the change in values of measures of interest between baseline and week 12. β [difference in the mean outcomes measures between treatment groups (probiotic plus selenium group = 1 and placebo group = 0)]
bObtained from multiple regression model (adjusted for baseline values of each biochemical variables, age and baseline BMI)
BDI beck depression inventory, DASS depression anxiety and stress scale, GHQ general health questionnaire, GSH total glutathione, hs-CRP high-sensitivity C-reactive protein, mF-G modified Ferriman Gallwey, MDA malondialdehyde, NO nitric oxide, SHBG sex hormone-binding globulin, TAC total antioxidant capacity